Diametric Capital’s HTG Molecular Diagnostics HTGM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-1,499
Closed -$179K – 157
2019
Q3
$179K Buy
1,499
+50
+3% +$10.1K 0.15% 91
2019
Q2
$433K Buy
1,449
+808
+126% +$337K 0.27% 77
2019
Q1
$288K Sell
641
-8
-1% -$3.5K 0.24% 83
2018
Q4
$297K Buy
649
+292
+82% +$181K 0.22% 89
2018
Q3
$325K Buy
357
+19
+6% +$12.5K 0.28% 85
2018
Q2
$198K Buy
+338
New +$221K 0.19% 71

Other funds holding HTGM

Diametric Capital's HTGM Position: Q4 2019 in Review

Diametric Capital sold out of HTG Molecular Diagnostics (HTGM) in Q4 2019, closing a stake of 1,499 shares — an estimated $179K sold.

Diametric Capital first reported a position in HTGM in Q2 2018 and held it in 6 quarters. The position peaked at $433K in Q2 2019. 27 funds tracked by Wall St. Rank hold HTGM as of Q4 2019.

  • Diametric Capital reported no remaining HTG Molecular Diagnostics position as of Q4 2019 after selling out during the quarter.
  • Diametric Capital sold 1,499 HTG Molecular Diagnostics shares in Q4 2019, an estimated $179K.
  • Diametric Capital first reported a position in HTG Molecular Diagnostics in Q2 2018 and held it in 6 quarters.
  • Diametric Capital's HTG Molecular Diagnostics position peaked at $433K in Q2 2019.
  • 27 funds tracked by Wall St. Rank held HTG Molecular Diagnostics as of Q4 2019.

Based on Diametric Capital's 13F filing for Q4 2019, filed 14 Feb 2020.